Searched for
BIOPHARMACEUTICAL INVESTMENT
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...- Why the world is betting on China again, and what India must do about itChina's business environment prioritizes market share with strong government backing. The nation has shifted to high-quality, high-speed pr...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Global Market: Hong Kong IPO boom draws rising interest from overseas companiesHong Kong's stock market is seeing more foreign companies file for listings. Firms from countries like Indonesia and South Korea are explor...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- US stock market futures today: Why are Dow Jones and S&P 500 in red while Nasdaq turns green today? Dow drops 280 points as oil tops $120— can AI spending offset rising inflation fears and Fed uncertainty?Why are Dow Jones and S&P 500 in red while Nasdaq turns green today? The US stock market futures today are sending a sharp, layered signal....
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Samsung to invest $356 billion over five years in strategic sectorsSouth Korea's top conglomerate said on Tuesday the investments through 2026 are expected to help Samsung drive long-term growth in strategi...
- CCI clears Phoenix Parentco's acquisition of Parexel International CorporationThe proposed transaction pertains to acquisition of 100 per cent of the equity shareholding of Parexel International, according to a notice...
- National Biopharma Mission launchedNew Delhi, June 30 (IANS) The National Biopharma Mission aimed at accelerating biopharmaceutical development in the country was launched by...
- Samsung Group, Quintiles to form drug ventureSamsung Electronics, the world's biggest manufacturer of flat screen televisions and computer memory chips, will hold 40 per cent of the ve...
- Licensing deals help Biocon post healthy Q3 nosBiocon's third quarter consolidated net profit rose 24% to 100.75 helped by inflows from licensing deals with global biggies Pfizer and Myl...
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
- Mauritius-based FIIs to pick up 47% in Intas' biotech armA clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
- Intas mfg unit gets EU-GMP certificationIntas Biopharmaceuticals Ltd (IBPL) has received European Union-good manufacturing practices (EU-GMP) certification for its manufacturing f...
Load More
